HC Wainwright Issues Pessimistic Outlook for CGEM Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Cullinan Therapeutics in a report released on Monday, August 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.90) per share for the quarter, down from their previous estimate of ($0.87). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.01) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.53) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.78) EPS, Q3 2027 earnings at ($0.80) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($3.17) EPS.

Several other research firms also recently commented on CGEM. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Wedbush reissued an “outperform” rating and issued a $37.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, June 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Finally, BTIG Research upped their price target on Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.14.

Cullinan Therapeutics Stock Up 7.4%

Shares of CGEM stock opened at $19.63 on Wednesday. The firm has a market cap of $1.26 billion, a P/E ratio of -6.33 and a beta of 0.01. The company has a 50 day moving average of $16.72 and a 200-day moving average of $14.94. Cullinan Therapeutics has a 12-month low of $5.68 and a 12-month high of $19.82.

Cullinan Therapeutics (NASDAQ:CGEM) last released its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01).

Institutional Investors Weigh In On Cullinan Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Cullinan Therapeutics in the second quarter worth $95,289,000. Affinity Asset Advisors LLC raised its stake in shares of Cullinan Therapeutics by 632.4% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company’s stock valued at $19,997,000 after purchasing an additional 1,668,289 shares during the period. Blue Owl Capital Holdings LP bought a new stake in shares of Cullinan Therapeutics during the 2nd quarter valued at $28,039,000. Lynx1 Capital Management LP lifted its holdings in Cullinan Therapeutics by 31.0% during the 3rd quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company’s stock worth $34,193,000 after purchasing an additional 1,365,248 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Cullinan Therapeutics during the 4th quarter worth about $12,803,000. Institutional investors own 86.31% of the company’s stock.

Insider Activity

In other news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $17.82, for a total value of $142,560.00. Following the sale, the insider owned 162,844 shares of the company’s stock, valued at $2,901,880.08. The trade was a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 8.60% of the stock is currently owned by company insiders.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $30 price target, implying substantial upside from the stock’s recent level near $19.63. The bullish target appears to be supporting investor sentiment, particularly as the shares trade close to their 52-week high.
• Neutral Sentiment: HC Wainwright projects continued quarterly losses but expects estimated EPS of ($0.77), ($0.78), ($0.80) and ($0.82) for the first four quarters of 2027, respectively, resulting in a projected FY2027 loss of ($3.17) per share. These forecasts provide investors with a view of the company’s expected cash-burning phase but do not signal near-term profitability.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS estimate to ($0.90) from ($0.87), Q4 2026 to ($0.93) from ($0.90), and FY2026 to ($3.53) from ($3.42). The revisions indicate somewhat higher expected losses and could limit gains despite the favorable rating and price target.
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day days-to-cover ratio. Because the figures appear incomplete or anomalous, they offer little actionable information about trading pressure.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.